for additional information on the contingent consideration , see note 3 to the consolidated financial statements included in this annual report on form 10-k. former aerospace segment divestiture in december 2011 , we sold the cargo systems and container businesses for approximately $ 280 mill ion and realized a gain of $ 126.8 million , net of tax . former commercial segment divestiture in march 2011 , we sold the marine businesses that were engaged in the design , manufacture and distribution of steering and throttle controls and engine and drive assemblies for the recreational marine market , heaters for commercial vehicles and burner units for military field feeding appliances for $ 123.1 million , consisting of $ 101.6 million in cash , net of $ 1.5 million of cash included in the marine business as part of the net assets sold , plus a subordinated promissory note in the amount of $ 4.5 million ( which has subsequently been repaid in full ) and the assumption by the buyer of approximately $ 15.5 million in liabilities related to the marine business . we realized a gain of $ 57.3 million , net of tax benefits , in connection with the sale . looking ahead , our strategy is to continue to be opportunistic and focus our attention on adding a combination of technology and strategic acquisitions to further strengthe n our existing product portfolio within the medical technology industry . additionally , we will continue to identify opportunities to expand our margins by evaluating our existing product portfolio and shedding product lines that do not meet our financial criteria as well as optimizing our overall facility footprint to further reduce our cost base . health care reform on march 23 , 2010 the patient protection and affordable care act was signed into law . t his legislation will have a significant impact on our business . for medical device companies such as teleflex , the expansion of medical insurance coverage should lead to greater utilization of the products we manufacture , but this legislation also contains provisions designed to contain the cost of healthcare , which could negatively affect pricing of our products . in addition , commencing in 2013 , the legislation imposes a 2.3 % excise tax on sales of medical devices . for the year ended december 31 , 2013 , we paid medical device excise taxes of $ 11.5 million , which is included in selling , general and administrative expenses . global economic conditions global economic conditions have had adverse impacts on market activities including , among other things , failure of financial institutions , falling asset values , diminished liquidity , and reduced demand for products and services . i n response , we adjusted production levels and engaged in new restructuring activities and we continue to review and evaluate our manufacturing , warehousing and distribution processes to maximize efficiencies through the elimination of redundancies in our operations and the consolidation of facilities . although , on a consolidated basis , the economic conditions did not have a significant adverse impact on our financial position , results of operations or liquidity , healthcare policies and practice trends vary by country , and the impact of the global economic downturn was felt to varying degrees in each of our regional markets over the last three years . the continuation of the present broad economic trends of weak economic growth , constricted credit and public sector austerity measures in response to growing public budget deficits could adversely affect our operations and our liquidity . hospitals in some regions of the united states experienced a decline in admissions , a weaker payor mix , and a reduction in elective procedures . hospitals consequently took actions to reduce their costs , including limiting their capital spending . distributors in the supply chain generally have reduced inventory levels and have not replenished inventories to pre-recession levels . the impact of these actions is most pronounced in capital goods markets , which affected our surgical instrument and cardiac assist businesses . more recently , the economic environment has improved somewhat , but has not returned to pre-recession levels , and challenges persist , particularly in some european countries , as discussed below . approximately 92 percent of our net revenues come from single-use products primarily used in critical care and surgical applications , and our sales volume could be negatively impacted if hospital admission rates or payor mix change as a result of continuing high unemployment rates ( and subsequent loss of insurance coverage by consumers ) . conversely , our sales volume could be positively impacted if there are additional insured individuals resulting from the patient protection and affordable care act . 35 in europe , some countries have taken austerity measures due to the current economic climate . elective surgeries have been delayed and hospital budgets have been reduced . in certain countries ( mainly germany ) we have seen changes in the local reimbursement to home care patients and pricing impacts on business awarded through the tendering process . these markets have introduced more buying groups and group purchasing organizations , or gpos , resulting in reductions in commodity product pricing . it is possible that funding for publically funded healthcare institutions could be affected in the future as governments make further spending adjustments and enact healthcare reform measures to lower overall healthcare costs . the public healthcare systems in certain countries in western europe , most notably greece , spain , portugal and italy , have experienced significantly reduced liquidity due to recessionary conditions , which has resulted in a slowdown in payments to us . we believe this situation will continue and may worsen unless and until these countries are able to find alternative means of funding their respective public healthcare sectors . in asia , recovery from the global recession has varied by country . story_separator_special_tag we expect to realize annual pre-tax savings in the range of $ 7- $ 10 million by the end of 2015 when these restructuring actions are complete . 2012 restructuring charges in 2012 , we identified opportunities to improve our supply chain strategy by consolidating three of our north american warehouses into one centralized warehouse , and lower costs and improve operating efficiencies through the termination of certain distributor agreements in europe , the closure of certain north american facilities and workforce reductions . the se projects will entail costs related to reductions in force , contract terminations related to distributor agreements and 40 leases , and facility closure and other costs . during 2013 , we incurred restructuring charges of $ 4.2 million and , as of december 31 , 2013 , we had recorded a reserve of $ 1.5 million related to these projects . we expect to complete the projects within the next twelve months . we expect future restructuring expenses associated with this restructuring program , if any , to be nominal . 2011 restructuring program in 2011 , we initiated a restructuring program at three facilities to consolidate operations and reduce costs . in connection with this program , we recorded contract termination costs of approximately $ 2.6 million associated with a lease termination , as we vacated 50 % of the premises during 2011. in addition , we recorded approximately $ 0.4 million for employee termination benefits in connection with workforce consolidations . in 2013 , we incurred approximately $ 0.8 million in contract termination costs and facility closure costs in connection with our exit from the remaining portion of the leased facility . the 2011 restructuring program was completed during 2013 . 2007 arrow integration program in connection with our acquisition of arrow international , inc. ( “ arrow ” ) in 2007 , we formulated a plan to integrate arrow and our other businesses . costs related to actions that affected employees and facilities of teleflex were charged to earnings and included in restructuring and other impairment char ges within the consolidated statement of operations . in 2012 we reversed approximately $ 2.0 million of contract termination costs related to a settlement of a dispute involving the termination of a european distributor agreement that was established in connection with our acquisition of arrow . the arrow integration plan was completed during 2013. impairment charges in-process research and development impairments in the fourth quarter 2013 , we recorded a $ 2.9 million in-process research and development ( “ ipr & d ” ) charge after we made the decision to abandon a research and development project associated with our vascular business . in the first quarter 2013 , we recorded a $ 4.5 million ipr & d charge pertaining to a research and development project associated with the axiom acquisition because technological feasibility had not yet been achieved and we determined that the subject technology had no future alternative use . in may 2012 , we acquired semprus , a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications . as of december 31 , 2013 , we continue to experience difficulties with respect to the development of the semprus technology , which we are attempting to resolve through further research and testing . failure to resolve these issues may result in a reduction of the expected future cash flows related to the semprus technology and could result in recognition of impairment charges with respect to the related assets , which could be material . as of december 31 , 2013 , we have recorded net assets of $ 42 million related to this investment . long-lived asset impairment in the third quarter 2013 , we recorded $ 3.5 million in impairment charges related to assets held for sale that had a carrying value in excess of their appraised fair value . investments in affiliates impairment during 2011 , we recognized net impairment charges of $ 2.5 million related to the decline in value of our investments in affiliates that are considered to be other than temporary . in making this determination , we considered multiple factors , including our intent and ability to hold investments , operating losses of investees that demonstrate an inability to recover the carrying value of the investments , the investee 's liquidity and cash position and market acceptance of the investee 's products and services . for additional information regarding our restructuring programs and impairment charges , see note 4 to the consolidated financial statements included in this annual report on form 10-k. 41 interest income and expense replace_table_token_13_th interest expense decreased for the twelve months ended december 31 , 2013 , compared to the corresponding period in 2012 , primarily because 2012 interest expense included amortization expense related to our termination of an interest rate swap ( approximately $ 11.1 million for the twelve months ended december 31 , 2012 ) . we terminated our agreement related to the interest rate swap , covering a notional amount of $ 350 million , in 2011. the unrealized losses within accumulated other comprehensive income associated with our interest rate swap were reclassified into our statement of income ( loss ) during 2012. interest expense decreased $ 0.7 million in 2012 compared to 2011 due to lower average interest rates , partially offset by approximately $ 15 million higher average outstanding debt . story_separator_special_tag style= `` margin-bottom:0pt ; margin-top:0pt ; margin-left:3.33 % ; margin-right:0 % ; text-indent:0 % ; font-family : arial ; font-weight : bold ; ; `` > comparison of 2012 and 2011 americas americas net revenues increased 5.6 % in 2012 compared to the corresponding period in 2011. the increase includes approximately $ 14.6 million related to acquisitions in 2012 , primarily lma ; $ 9.5 million related to new product sales , primarily in vascular , anesthesia , respiratory and surgical products ; price increases of

loss on extinguishments of debt replace_table_token_14_th during the third quarter of 2013 , the company refinanced its $ 775.0 million senior credit facility comprised of a $ 375.0 million term loan and a $ 400.0 million revolving credit facility with a new $ 850.0 million senior credit facility consisting solely of a revolving credit facility . in connection with the refinancing the company recognized debt extinguishment costs of $ 1.3 million related to unamortized debt issuance costs . during 2011 , we recorded losses on the extinguishment of debt of $ 15.4 million as a result of the prepayment , in the first quarter of 2011 , of the remaining outstanding principal amount of our senior notes issued in 2004 ( the “ 2004 notes ” ) and the $ 125 million repayment , in the second quarter of 2011 , of term loan borrowings under our senior credit facility . in connection with the prepayment of our 2004 notes , we recognized debt extinguishment costs of approximately $ 14.6 million related to the prepayment “ make-whole ” amount of $ 13.9 million paid to the holders of the 2004 notes and the write-off of $ 0.7 million of unamortized debt issuance costs that we incurred prior to the prepayment of the 2004 notes . during the second quarter of 2011 , we recorded a $ 0.8 million write-off of unamortized debt issuance costs as a loss on extinguishment of debt in connection with the $ 125 million repayment of term loan borrowings . see note 8 to the consolidated financial statements included in this annual report on form 10-k for further information . taxes on income from continuing operations replace_table_token_15_th the effective income tax rate in 2013 was 13.4 % compared to ( 9.9 % ) in 2012. taxes on income from continuing operations in 2013 were $ 23.5 million compared to $ 16.4 million in 2012. the effective tax rate for 2013 was impacted by the realization of net tax benefits resulting from the expiration of statutes of limitation for u.s. federal and state and foreign matters , tax benefits associated with u.s. and foreign tax return filings and the realization of tax benefits resulting from the resolution of a foreign tax matter .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```loss on extinguishments of debt replace_table_token_14_th during the third quarter of 2013 , the company refinanced its $ 775.0 million senior credit facility comprised of a $ 375.0 million term loan and a $ 400.0 million revolving credit facility with a new $ 850.0 million senior credit facility consisting solely of a revolving credit facility . in connection with the refinancing the company recognized debt extinguishment costs of $ 1.3 million related to unamortized debt issuance costs . during 2011 , we recorded losses on the extinguishment of debt of $ 15.4 million as a result of the prepayment , in the first quarter of 2011 , of the remaining outstanding principal amount of our senior notes issued in 2004 ( the “ 2004 notes ” ) and the $ 125 million repayment , in the second quarter of 2011 , of term loan borrowings under our senior credit facility . in connection with the prepayment of our 2004 notes , we recognized debt extinguishment costs of approximately $ 14.6 million related to the prepayment “ make-whole ” amount of $ 13.9 million paid to the holders of the 2004 notes and the write-off of $ 0.7 million of unamortized debt issuance costs that we incurred prior to the prepayment of the 2004 notes . during the second quarter of 2011 , we recorded a $ 0.8 million write-off of unamortized debt issuance costs as a loss on extinguishment of debt in connection with the $ 125 million repayment of term loan borrowings . see note 8 to the consolidated financial statements included in this annual report on form 10-k for further information . taxes on income from continuing operations replace_table_token_15_th the effective income tax rate in 2013 was 13.4 % compared to ( 9.9 % ) in 2012. taxes on income from continuing operations in 2013 were $ 23.5 million compared to $ 16.4 million in 2012. the effective tax rate for 2013 was impacted by the realization of net tax benefits resulting from the expiration of statutes of limitation for u.s. federal and state and foreign matters , tax benefits associated with u.s. and foreign tax return filings and the realization of tax benefits resulting from the resolution of a foreign tax matter .
```    
 Suspicious Activity Report : for additional information on the contingent consideration , see note 3 to the consolidated financial statements included in this annual report on form 10-k. former aerospace segment divestiture in december 2011 , we sold the cargo systems and container businesses for approximately $ 280 mill ion and realized a gain of $ 126.8 million , net of tax . former commercial segment divestiture in march 2011 , we sold the marine businesses that were engaged in the design , manufacture and distribution of steering and throttle controls and engine and drive assemblies for the recreational marine market , heaters for commercial vehicles and burner units for military field feeding appliances for $ 123.1 million , consisting of $ 101.6 million in cash , net of $ 1.5 million of cash included in the marine business as part of the net assets sold , plus a subordinated promissory note in the amount of $ 4.5 million ( which has subsequently been repaid in full ) and the assumption by the buyer of approximately $ 15.5 million in liabilities related to the marine business . we realized a gain of $ 57.3 million , net of tax benefits , in connection with the sale . looking ahead , our strategy is to continue to be opportunistic and focus our attention on adding a combination of technology and strategic acquisitions to further strengthe n our existing product portfolio within the medical technology industry . additionally , we will continue to identify opportunities to expand our margins by evaluating our existing product portfolio and shedding product lines that do not meet our financial criteria as well as optimizing our overall facility footprint to further reduce our cost base . health care reform on march 23 , 2010 the patient protection and affordable care act was signed into law . t his legislation will have a significant impact on our business . for medical device companies such as teleflex , the expansion of medical insurance coverage should lead to greater utilization of the products we manufacture , but this legislation also contains provisions designed to contain the cost of healthcare , which could negatively affect pricing of our products . in addition , commencing in 2013 , the legislation imposes a 2.3 % excise tax on sales of medical devices . for the year ended december 31 , 2013 , we paid medical device excise taxes of $ 11.5 million , which is included in selling , general and administrative expenses . global economic conditions global economic conditions have had adverse impacts on market activities including , among other things , failure of financial institutions , falling asset values , diminished liquidity , and reduced demand for products and services . i n response , we adjusted production levels and engaged in new restructuring activities and we continue to review and evaluate our manufacturing , warehousing and distribution processes to maximize efficiencies through the elimination of redundancies in our operations and the consolidation of facilities . although , on a consolidated basis , the economic conditions did not have a significant adverse impact on our financial position , results of operations or liquidity , healthcare policies and practice trends vary by country , and the impact of the global economic downturn was felt to varying degrees in each of our regional markets over the last three years . the continuation of the present broad economic trends of weak economic growth , constricted credit and public sector austerity measures in response to growing public budget deficits could adversely affect our operations and our liquidity . hospitals in some regions of the united states experienced a decline in admissions , a weaker payor mix , and a reduction in elective procedures . hospitals consequently took actions to reduce their costs , including limiting their capital spending . distributors in the supply chain generally have reduced inventory levels and have not replenished inventories to pre-recession levels . the impact of these actions is most pronounced in capital goods markets , which affected our surgical instrument and cardiac assist businesses . more recently , the economic environment has improved somewhat , but has not returned to pre-recession levels , and challenges persist , particularly in some european countries , as discussed below . approximately 92 percent of our net revenues come from single-use products primarily used in critical care and surgical applications , and our sales volume could be negatively impacted if hospital admission rates or payor mix change as a result of continuing high unemployment rates ( and subsequent loss of insurance coverage by consumers ) . conversely , our sales volume could be positively impacted if there are additional insured individuals resulting from the patient protection and affordable care act . 35 in europe , some countries have taken austerity measures due to the current economic climate . elective surgeries have been delayed and hospital budgets have been reduced . in certain countries ( mainly germany ) we have seen changes in the local reimbursement to home care patients and pricing impacts on business awarded through the tendering process . these markets have introduced more buying groups and group purchasing organizations , or gpos , resulting in reductions in commodity product pricing . it is possible that funding for publically funded healthcare institutions could be affected in the future as governments make further spending adjustments and enact healthcare reform measures to lower overall healthcare costs . the public healthcare systems in certain countries in western europe , most notably greece , spain , portugal and italy , have experienced significantly reduced liquidity due to recessionary conditions , which has resulted in a slowdown in payments to us . we believe this situation will continue and may worsen unless and until these countries are able to find alternative means of funding their respective public healthcare sectors . in asia , recovery from the global recession has varied by country . story_separator_special_tag we expect to realize annual pre-tax savings in the range of $ 7- $ 10 million by the end of 2015 when these restructuring actions are complete . 2012 restructuring charges in 2012 , we identified opportunities to improve our supply chain strategy by consolidating three of our north american warehouses into one centralized warehouse , and lower costs and improve operating efficiencies through the termination of certain distributor agreements in europe , the closure of certain north american facilities and workforce reductions . the se projects will entail costs related to reductions in force , contract terminations related to distributor agreements and 40 leases , and facility closure and other costs . during 2013 , we incurred restructuring charges of $ 4.2 million and , as of december 31 , 2013 , we had recorded a reserve of $ 1.5 million related to these projects . we expect to complete the projects within the next twelve months . we expect future restructuring expenses associated with this restructuring program , if any , to be nominal . 2011 restructuring program in 2011 , we initiated a restructuring program at three facilities to consolidate operations and reduce costs . in connection with this program , we recorded contract termination costs of approximately $ 2.6 million associated with a lease termination , as we vacated 50 % of the premises during 2011. in addition , we recorded approximately $ 0.4 million for employee termination benefits in connection with workforce consolidations . in 2013 , we incurred approximately $ 0.8 million in contract termination costs and facility closure costs in connection with our exit from the remaining portion of the leased facility . the 2011 restructuring program was completed during 2013 . 2007 arrow integration program in connection with our acquisition of arrow international , inc. ( “ arrow ” ) in 2007 , we formulated a plan to integrate arrow and our other businesses . costs related to actions that affected employees and facilities of teleflex were charged to earnings and included in restructuring and other impairment char ges within the consolidated statement of operations . in 2012 we reversed approximately $ 2.0 million of contract termination costs related to a settlement of a dispute involving the termination of a european distributor agreement that was established in connection with our acquisition of arrow . the arrow integration plan was completed during 2013. impairment charges in-process research and development impairments in the fourth quarter 2013 , we recorded a $ 2.9 million in-process research and development ( “ ipr & d ” ) charge after we made the decision to abandon a research and development project associated with our vascular business . in the first quarter 2013 , we recorded a $ 4.5 million ipr & d charge pertaining to a research and development project associated with the axiom acquisition because technological feasibility had not yet been achieved and we determined that the subject technology had no future alternative use . in may 2012 , we acquired semprus , a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications . as of december 31 , 2013 , we continue to experience difficulties with respect to the development of the semprus technology , which we are attempting to resolve through further research and testing . failure to resolve these issues may result in a reduction of the expected future cash flows related to the semprus technology and could result in recognition of impairment charges with respect to the related assets , which could be material . as of december 31 , 2013 , we have recorded net assets of $ 42 million related to this investment . long-lived asset impairment in the third quarter 2013 , we recorded $ 3.5 million in impairment charges related to assets held for sale that had a carrying value in excess of their appraised fair value . investments in affiliates impairment during 2011 , we recognized net impairment charges of $ 2.5 million related to the decline in value of our investments in affiliates that are considered to be other than temporary . in making this determination , we considered multiple factors , including our intent and ability to hold investments , operating losses of investees that demonstrate an inability to recover the carrying value of the investments , the investee 's liquidity and cash position and market acceptance of the investee 's products and services . for additional information regarding our restructuring programs and impairment charges , see note 4 to the consolidated financial statements included in this annual report on form 10-k. 41 interest income and expense replace_table_token_13_th interest expense decreased for the twelve months ended december 31 , 2013 , compared to the corresponding period in 2012 , primarily because 2012 interest expense included amortization expense related to our termination of an interest rate swap ( approximately $ 11.1 million for the twelve months ended december 31 , 2012 ) . we terminated our agreement related to the interest rate swap , covering a notional amount of $ 350 million , in 2011. the unrealized losses within accumulated other comprehensive income associated with our interest rate swap were reclassified into our statement of income ( loss ) during 2012. interest expense decreased $ 0.7 million in 2012 compared to 2011 due to lower average interest rates , partially offset by approximately $ 15 million higher average outstanding debt . story_separator_special_tag style= `` margin-bottom:0pt ; margin-top:0pt ; margin-left:3.33 % ; margin-right:0 % ; text-indent:0 % ; font-family : arial ; font-weight : bold ; ; `` > comparison of 2012 and 2011 americas americas net revenues increased 5.6 % in 2012 compared to the corresponding period in 2011. the increase includes approximately $ 14.6 million related to acquisitions in 2012 , primarily lma ; $ 9.5 million related to new product sales , primarily in vascular , anesthesia , respiratory and surgical products ; price increases of

